In conclusion, these data enhanced our fundamental understanding of the importance of tumor-reactive CD4+ T cells in the context of ACT and expanded the spectrum of CD4+ T cell-mediated anti-tumor immunity. This evidence concerns the gene CD4 and neoplasm.